anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The standard protocol at the unit, which comprises mouthwash with chlorhexidine 0,12%; oral hygiene teaching. In case the toothbrush cannot be used due to gingival or oral mucosa bleeding, gauze is used to replace it.
The invention relates to a contrast agent and particularly relates to a dual-mode synergistically-enhanced magnetic-resonance contrast agent and a method for synthesizing the same. The dual-mode synergistically-enhanced magnetic-resonance contrast agent is synthesized in one pot by taking the compound of a contrasting material T1 and a contrasting material T2 as a reaction precursor. The method comprises the following steps of: dissolving gadolinium oleate or gadolinium acetylacetone and ferric oleate or ferric acetylacetonate into octadecene or benzyl ether, adding oleic acid, heating an obtained solution, carrying out reflux reaction to obtain a reaction solution, cooling to room temperature, adding a first solvent to precipitate a product of reaction, centrifuging, removing a supernate, and dissolving a precipitate into a second solvent. The method is simple in steps, is convenient to operate, ensures high yield and is suitable for large-scale preparation. The idea of doping and synthesizing ensures that the field directions of the contrasting material T1 and the contrasting material T2 are parallel and same in the external magnetic field. The dual-mode contrast agent synthesized from the contrasting material T1 and the contrasting material T2 has the capacity of making two imaging modes complementary to each other and can obtain two imaging results nearly at the same time in the same place under the same resolution.
Subjects randomized to the standard care arm will begin HAART with TDF/FTC/ATV/r (preferred), AZT/3TC/ATV/r, or other recommended ATV/r based HAART regimen according to current DHHS standard of care and will be followed for a total of three years. Under these guidelines and under current clinical standards, subjects on the standard care arm will begin therapy when the CD4+ T cell count drops below 350 cells/mm3 or other clinical criteria necessitating treatment as determined by the site clinician occur.
The inventions relate to cosmetology and are intended to increase a cosmetic effect. A mask comprises a cream-type cosmetic agent and an additional reagent, which are isolated from one another. The agent contains a water-soluble biocompatible polymer which has a mass in the range of 50,000-1,000,000 Da and is capable of entering into a cross-polymerisation reaction. The reagent consists of a substance-electrolyte solution containing multicharged ions. The mass ratio of polymer and substance-electrolyte is from 10:1 to 1:1 respectively. A method involves separately applying to the skin the cream-type agent and then the additional reagent on top.
FIELD: medicine, ophthalmology, pharmacy. SUBSTANCE: composition has para-aminobenzoic acid and pharmaceutically acceptable additions at mass ratio = (0.00007-0.007):1, respectively. Composition has NaCl solution, boric acid and laevomycetin solution, boric acid solution and others as additions. Composition can be liquid for drop, injection and external using or an ointment. Composition has small amount of para-aminobenzoic acid that ensures to use its in ophthalmology. EFFECT: enhanced effectiveness of composition. 10 cl
The side effects most frequently reported with phenothiazine compounds are extrapyramidal symptoms including pseudoparkinsonism, dystonia, dyskinesia, akathisia, oculogyric crises, opisthotonos, and hyperreflexia. Most often these extrapyramidal symptoms are reversible; however, they may be persistent (see below). With any given phenothiazine derivative, the incidence and severity of such reactions depend more on individual patient sensitivity than on other factors, but dosage level and patient age are also determinants.

Symptoms of dystonia, prolonged abnormal contractions of muscle groups, may occur in susceptible individuals during the first few days of treatment. Dystonic symptoms include: spasm of the neck muscles, sometimes progressing to tightness of the throat, swallowing difficulty, difficulty breathing, and/or protrusion of the tongue. While these symptoms can occur at low doses, they occur more frequently and with greater severity with high potency and at higher doses of first generation antipsychotic drugs. An elevated risk of acute dystonia is observed in males and younger age groups.

Extrapyramidal reactions may be alarming, and the patient should be forewarned and reassured. These reactions can usually be controlled by administration of antiparkinsonian drugs such as Benztropine Mesylate or Intravenous Caffeine and Sodium Benzoate Injection, and by subsequent reduction in dosage.
In this arm, 10 ketosis prone diabetes patients will be randomly assigned to receive 34.2 mmol/d of dietary citrulline for 20 days. Citrulline will be in the form of 2.85 mmol capsules and patients will be instructed to consume 4 capsules with each of their 3 main meals. The citrulline will be provided in a double-blind fashion by a designated unblinded investigator who will not come in direct contact with the subjects.
HER2+ breast cancer patients with brain metastases will receive a single IV dose of 2B3-101 on day 1 of each cycle. In order to minimize the risk of infusion reactions 5% of the total dose of 2B3-101 (in mg) should be infused slowly over the first 30 minutes. As long as 2B3-101 is well tolerated, the remaining 95% of the infusion could thereafter be administered over the next 60 min, resulting in a total infusion time of 90 minutes. The infusion of trastuzumab will then follow 30 minutes after the completion of the 2B3-101 infusion.
BACKGROUND: With an increasing collection of patient-reported outcomes (PROs) to measure health-related quality of life (HRQoL) in oncological patients, there is still a lack of standardised strategies on how to interpret and use these data in patient care. Prior research has shown support for the use of digital PRO monitoring together with alarm systems to notify clinicians when the PRO values are deteriorating. This system has demonstrated advantages in improving HRQoL and increasing survival rates among oncology patients. Hence, we designed the PRO B study, a superiority multi-centre randomised controlled trial, to investigate the effects of alarm-based monitoring in metastatic breast cancer patients in Germany. The study protocol for the PRO B study was published in September 2021, and this manuscript describes a formal statistical analysis plan (SAP) for the PRO B study to improve the transparency and quality of this trial.
METHODS AND DESIGN: The trial aimed to recruit 1000 patients with metastatic breast cancer. However, as of the completion of recruitment on June 15, 2023, we have successfully enrolled 924 patients from 52 breast cancer centres. Patients were 1:1 stratified randomised to the intervention and control groups. App-based PRO questionnaires are sent weekly to the intervention group and every 3 months to the control group. Only patients in the intervention group trigger an alarm if their PRO scores deteriorate, and they are subsequently contacted by the local care team within 48 h. The primary outcome is the fatigue score at 6 months, and secondary outcomes are other HRQoL and overall survival. Evaluation of the superiority of the intervention will be done using a linear mixed model with random intercepts for study centres.
CONCLUSION: This detailed SAP defines the main components of the statistical analysis for the PRO B study to assist the statistician and prevent bias in selecting analysis and reporting findings. Version 1 of the SAP was finalised on January 18, 2024.
TRIAL REGISTRATION: DRKS (German Clinical Trials Register) DRKS00024015 . Registered on February 15, 2021.
The hormone is applied in biotechnology and medicine for diagnostic and experimental purposes. The method is easily implementable and it derives a hormone of relatively high output - from 20 to 30 mkg/g of tissue, with specific activity of 11.2 ME/mg of protein and enhanced summating hormonal activity calculated on the basis of weight of hypophisic tissue. It consists of extraction of frozen and homogeneized human hypophisic glands with a buffer, centrifusion and subsequent precipitation with ammonium sulphate. The extraction is carried out with a buffer at pH from 8.4 to 8.6, while the homogen is centrifuged at low revolutions. The supernatante is subject to ionic exchange chromatography, the protein is eluated and the derived eluate is precipitated with ammonium sulphate and is centrifuged at low revolutions, after which the precipitation is consecutively solved, desalinated and concentrated via ultra-filtration. The concentrate is subject to ionic-exchange chromatography, then eluation and the eluate is treated through adsorption chromatography. The hormonal product is eluated. The derived eluate is concentrated through ultra-filtration and the concentrate is cleansed through gel-filtration.
Only applicable in part 3 which is a randomized controlled trial. Part 1 and part 2 are the prospective cohort studies.
<P>PROBLEM TO BE SOLVED: To provide a medicament having a new mechanism of action for modifying functions (production of cytokine/chemokine) of an NK cell bearing important roll in biophylaxis against infection/tumor or the like, and to provide a method for screening the medicament.  <P>SOLUTION: The modifier selective to the production of the cytokine and/or chemokine in the NK cell contains a material capable of modifying the expression or function of constituent factors (e.g. Carmal and Bcl10) of a CBM complex, participating in the activation of the NK cell. The method for screening the material capable of selectively modifying the production of the cytokine and/or the chemokine in the NK cell includes evaluating whether a specimen modifies the expression or function of the constituent factor of the CBM complex. The NK cell wherein the expression or function of the constituent factor of the CBM complex is modified is also provided.  <P>COPYRIGHT: (C)2008,JPO&INPIT
Home delivered meal programs provide essential health and nutritional support to community-dwelling older adults in the United States. Without this support, nearly three million older adults would be at even greater risk for malnourishment and subsequent health decline, leading to potential hospitalizations and nursing home placements. Despite the reported value of home delivered meals, the increasingly complex health needs of the older adult population warrant new, innovative approaches that enhance home-delivered meal services. In our prior work, we identified that the majority of home delivered meal clients are at high risk for malnutrition, increasing clients' risk of falling and warranting the need for registered dietitian services to attenuate health decline. Additionally, our other work has identified that 80% of home delivered meal clients are at elevated risk for falling,6 and over 40% have experienced a fall in the past year. The high prevalence of fall risk factors among home delivered clients suggests that additional services - such as occupational therapy - are also needed to optimize clients' ability to safely remain living in their own homes and communities. In response to home delivered meal clients' need for more enhanced and specialized services, the present study will test four different service models to determine which model is most effective for reducing fall-related outcomes.
Exercise Intervention \& Nutritional Intervention. Participants undergo instructor-led exercise and nutrition education classes for 60 minutes twice a week for 12 weeks.
PURPOSE:A novel trichogenic promoter, obtained by incorporating one or more of cholesterone, stigmasterone, campesterone and beta-sitosterone selected from various steroid compounds with other components, and capable of preventing the premature baldness and depilation. CONSTITUTION:A trichogenic promoter obtained by incorporating one or more of cholesterone, stigmasterone and beta-sitosterone with other components. The above-mentioned formulation is capable of inhibiting (preventing) the acivation of estradiol-17beta-dehydrogenase, and sustaining female hormonal action. Therefore, effect on promoting hair production is enhanced. The above-mentioned formulation is contained in an extract obtained by extracting a trunk or branch of Japanese quassia wood (Picrasma ailanthoides Planch.) or rubber tree (Hevea brasiliensis) with an organic solvent or in a crude reaction product obtained from commercially available cholesterol, campesterol, stigmasterol or beta-sitosterol as a row material.
These participants will perform moderate intensity interval training. The intervention will be applied thrice a week. Moderate intensity interval training in which they do stair climbing 3 times a week And for every 1 interval I will ask them to take rest for 3 minutes.
Patients received an aliskiren 150 mg tablet, a HCTZ 12.5 mg capsule and a placebo capsule for the first 3 days of treatment. Amlodipine 5 mg was then added for the remainder of the first 4 weeks of treatment. At the end of 4 weeks, patients were force titrated up to aliskiren / amlodipine / hydrochlorothiazide 300/10/25 mg for the remaining 4 weeks of the study. During the 8 weeks, patients also received a placebo tablet. Patients took a total of 4 pills each day orally with water in the morning at approximately 8:00 am, except on the morning of a study visit when they took their study medications after all visit procedures and assessments had been completed.
In recent years, the spread of HIV and other STDs has increased, especially among men who have sex with men. This increase signifies continued sexual risk taking within this population. In order to curb the increase of HIV infections, prevention programs are needed. A standard prevention case management program has been developed; however, new programs that further improve outcomes are needed. This study will evaluate the effectiveness of a behavioral intervention program versus standard prevention case management (PCM) in promoting safer sex practices in HIV-infected men.

Participants in this 1-year open-label study will be randomly assigned to receive either PCM alone or a behavioral intervention called Project Enhance, in addition to PCM. The behavioral intervention will be administered by a trained medical social worker on an individual basis. It will include an education component, as well as motivational and behavioral skills enhancement. PCM will entail standard case management, as well as referrals to specific services that each individual may need. Treatment will occur for only the first 3 months, after which follow-up sessions will be held every 3 months for the remainder of the year.
PURPOSE: A cosmetic composition containing Kujeungkupo powder(9-time steamed powder) and a method for manufacturing the same are provided to ensure antioxidation, whitening, moisturizing, and anti-wrinkling effects. CONSTITUTION: A cosmetic composition contains Kujeungkupo powder and additives. The particle size of the powder is 0.1-1.0 mm. The powder is yuzu peel powder, black ginseng powder, black Platycodon grandiflorum (Jacq.) A.DC. powder, or black green tea powder which is steamed and dried nine times and pulverizing. The additives contain an emulsifier, a moisturizing agent, and purified water.
FARYDAK should be taken orally once on each scheduled day at about the same time, either with or without food [see Clinical Pharmacology (12.3)].

FARYDAK capsules should be swallowed whole with a cup of water. Do not open, crush, or chew the capsules [see How Supplied/Storage and Handling (16)].

If a dose is missed it can be taken up to 12 hours after the specified dose time. If vomiting occurs the patient should not repeat the dose, but should take the next usual scheduled dose.

Counsel patients on the correct dosing schedule, technique of administration of FARYDAK, and when to take FARYDAK if dosing adjustments are made.

Prior to the start of FARYDAK treatment and during treatment, monitoring should include:

  * Complete Blood Count (CBC): Obtain a CBC before initiating treatment. Verify that the baseline platelet count is at least 100 x 109/L and the baseline absolute neutrophil count (ANC) is at least 1.5 x 109/L. Monitor the CBC weekly (or more often as clinically indicated) during treatment. [see Warnings and Precautions (5.4) Adverse Reactions (6.1)].
  * ECG: Perform an ECG prior to the start of therapy and repeat periodically during treatment as clinically indicated. Verify that the QTcF is less than 450 msec prior to initiation of treatment with FARYDAK. If during treatment with FARYDAK, the QTcF increases to ≥480 msec, interrupt treatment. Correct any electrolyte abnormalities. If QT prolongation does not resolve, permanently discontinue treatment with FARYDAK [see Warnings and Precautions (5.2), Adverse Reactions (6.1)]. During the clinical trial, ECGs were performed at baseline and prior to initiation of each cycle for the first 8 cycles.
  * Serum Electrolytes: Obtain electrolytes, including potassium and magnesium, at baseline and monitor during therapy. Correct abnormal electrolyte values before treatment [see Warnings and Precautions (5.2), Adverse Reactions (6.1)]. During the trial, monitoring was conducted prior to the start of each cycle, at Day 11 of cycles 1 to 8, and at the start of each cycle for cycles 9 to 16.



For additional information please refer to the bortezomib and dexamethasone prescribing information.
PURPOSE:An antioxidant highly safe and suitable for food and cosmetic, primarily comprising an effective component contained in the leaf portion of a carrot. CONSTITUTION:The leaf of a carrot (Daucus carota L.) is dried and crushed. To the resulting crushed material is added about 10-20 times as much extractant such as water or methanol, and the mixture is heated under reflux at about 60- 90 deg.C for about 30-80min and filtered. After the obtd. filtrate is concentrated to an extent so as to contain about 30% extract, it is subjected to vacuum drying, freeze drying, spray drying, etc. to obtain a pale green powder (antioxidant). A high-purity antioxidant (a white powder) is obtd. by subsequent fractional purification and column chromatograhy.
Coronary function tests are measured and disclosed to the clinician for re-evaluation of the initial diagnosis and treatment as compared with initial angiography. The intervention involves measurement of FFR, CFR, IMR and RRR in a major coronary artery followed by reactivity testing using incremental doses of acetylcholine (10-4 Molar (M), 10-5 M, 10-6 M) to assess endothelial function, bolus of ACh (10-4 M; 100 micrograms) for vasospasm, followed by glyceryl trinitrate (300 micrograms). FFR will be measured in all arteries with a diameter \>=2.5 mm and a stenosis 40% to 90% in severity. Endotypes are based on criteria for abnormal coronary vasodilator function, vasospasm and microvascular resistance. The endotypes (diagnostic strata) are: obstructive CAD, vasospastic angina, microvascular angina, mixed (ie both vasospastic and microvascular disorders), endothelial dysfunction (no angina), normal (non-cardiac). A diagnosis may be ruled-in or ruled-out based on the test results.
The present invention relates to a method for preparing hollow microspheres used for lung administration. The method comprises the following steps: adding low boiling point solvent and surface acting agents into the aqueous solution of chitosan and/or polyvinylpyrrolidone, wherein the aqueous solution of chitosan and/or polyvinylpyrrolidone accounts for 0.8 to 3 wt% of the mixture, the low boiling point solvent accounts for 30 to 70 wt% of the mixture, and the surface acting agents are alkyl polyglycoside which acounts for 5 to 40 wt% of the chitosan and/or the polyvinylpyrrolidone; then carrying out spraying and drying to obtain the hollow microspheres of the present invention. The preparing method also comprises the steps of adding spherical silicon dioxide particles whose particle diameters are from 80 to 200 nm into the aqueous solution of the chitosan and/or the polyvinylpyrrolidone. The particle diameters of the hollow microspheres prepared by the present invention are smaller than 40 mu m, and can be adjusted. When used as carriers of medicines, the hollow microspheres can fly into alveolus and can not be phagocytized by macrophage because of large particle diameters. The hollow microspheres are especially suitable for powder inhalant to achieve the purpose of lung administration.
The present invention relates to use of a sugar or a sugar alcohol eg. glycerol for protection of skin against harmful bacteria. The present invention is especially useful in formulating compositions which act as prebiotics by skin commensal bacteria like <i>S</i>. <i>epidermidis</i> to produce metabolites like lactic acid which by way of the present invention has been shown to inhibit growth of harmful bacteria like <i>E. Coli</i> and <i>S</i>. Aureus. The present invention is advantageous in that there is no need to use conventional antimicrobial actives which may destroy the skin microbiome.
The management of head and neck cancers is multidisciplinary, often relying on the use of combined treatments to maximize the chances of cure. Combined treatments are however also responsible for cumulative side effects. The aim of reconstructive surgery with a flap is to restore a function lost with the loss of substance from the tumor resection. However, changes in reconstructive surgery have impact of postoperative radiotherapy planning. The optimization of imaging protocols for radiotherapy planning should make it possible to identify postoperative changes and to distinguish flaps from surrounding native tissues to delineate the flaps and document the spontaneous evolution of these flaps or dose-effect relationships in case of radiotherapy. Such changes include atrophy, fibrosis of soft tissue flaps and osteoradionecrosis of bone flaps. Radiotherapy optimization also involves standardization of the definition of target volumes in situations where a flap is present, a situation that is increasingly common in routine care. This evolution of practice, beyond the essential multidisciplinary consultation meetings defining treatment indications, requires a close radio surgical collaboration with respect to technical aspects of the two disciplines. Doing so, anticipation of relapse and toxicity profiles could possibly lead to propose strategies for personalized de-escalation of multimodal treatments through interdisciplinary trials.
OBJECTIVES: I. Determine the response to pulse calcitriol in patients with previously treated adenocarcinoma of the prostate with rising PSA levels. II. Assess the impact of this regimen on the slope of the PSA rise in these patients. III. Determine the qualitative and quantitative toxic effects of this regimen in these patients. IV. Assess the impact of this regimen on the quality of life of these patients.

OUTLINE: All patients remain on a reduced calcium diet for the duration of the study. Twelve hours prior to treatment, patients begin drinking 4-6 glasses of extra fluid for 3 days. Patients receive oral calcitriol over 4 hours weekly. Treatment continues in the absence of disease progression or unacceptable toxicity. Quality of life is assessed at baseline, every 4 weeks during treatment, and at the end of the study. Patients are followed for at least 1 month.

PROJECTED ACCRUAL: A total of 15-25 patients will be accrued for this study.